Protease expression, activity, and inhibition play crucial roles in a multitude of biological processes; however, these three aspects of their function are difficult for any one bioanalytical probe to measure. To help address this challenge, we report a multifunctional concentric Förster resonance energy transfer (FRET) configuration that combines two modes of biorecognition using aptamers and peptide substrates co-assembled to a central semiconductor quantum dot (QD). The aptamer is sensitive to the concentration of protease and the peptide is sensitive to its hydrolytic activity. The role of the QD is to serve as a nanoscale scaffold and initial donor for energy transfer with both Cyanine 3 (Cy3) and Alexa Fluor 647 (A647) fluorescent dyes associated with the aptamer and peptide, respectively. Using thrombin as a model protease, we
that modify the active site of a protease with a tag that can be directly or indirectly labeled for quantitation. 8 This approach provides a proxy measure for activity via the availability of active sites. Overall, none of the foregoing strategies measures both activity and concentration.
Here, we report a design for a fluorescent bioanalytical probe that is simultaneously sensitive to both protease activity and concentration, with the ability to resolve one from the other. The design, shown in Figure 1 , takes advantage of the physical and optical properties of semiconductor quantum dots (QDs) and uses thrombin as a model protease. Poly(ethylene glycol)-coated CdSeS/ZnS QDs with peak emission at 524 nm (QD524) are conjugated with multiple copies of an Alexa Fluor 647 (A647) dye-labeled peptide substrate for thrombin, as well as multiple copies of a thrombin-binding aptamer partially hybridized with a Cyanine 3 (Cy3)
dye-labeled oligonucleotide. The peptide is a probe for thrombin activity; the aptamer is a probe for thrombin concentration. Resolvable signals for protease activity and concentration are generated through adaptation of a concentric Förster resonance energy transfer (cFRET) configuration that we recently developed. 14 The QD524 serves as a highly efficient energy donor for the Cy3 and a less efficient energy donor for the A647, while the Cy3 also serves as a good energy donor for the A647. 14 The relative emission from the QD524, Cy3, and A647 can be calibrated to permit determination of the number of each acceptor per QD. Changes in emission are associated with proteolytic cleavage of the A647 from the QD, and with displacement of the Cy3-labeled oligonucleotide when thrombin-binding aptamer binds to thrombin, each resulting in loss of FRET pathways. These signaling mechanisms have been reported individually, 15, 16 but neither in combination on a common nanoparticle scaffold nor with cFRET. Whereas our previous cFRET probe was designed to detect the activity of two different proteases, this new cFRET probe is multifunctional in that it simultaneously combines two modes of biorecognition for a single protease. Active thrombin can be distinguished from inactive thrombin with reversible or irreversible inhibition of its active site, and thrombin activity can be distinguished from thrombin-like activity associated with other proteases. This strategy is therefore very promising for the bioanalysis of proteases and is uniquely facilitated by the properties of QDs. Table 1 for the aptamer and peptide sequences and abbreviations.) The configuration is designed such that active thrombin modulates all three FRET pathways, inactive thrombin (i.e., inhibited) modulates the QD-to-Cy3
and Cy3-to-A647 FRET pathways, and thrombin-like activity by other proteases modulates the QD-to-A647 and Cy3-to-A647 FRET pathways.
Experimental Section
Materials. Alloyed CdSeS/ZnS QDs (~6 nm diameter) with peak photoluminescence (PL) at 524 Inhibition assays. For these assays, probes were prepared as described above. In the case of Data analysis. In the cFRET configuration, PL ratios were calculated from the PL intensities measured at 524 nm, 564 nm, and 668 nm. At these wavelengths, the emission from the QD524, Cy3, and A647 were largely resolved, albeit that small corrections for crosstalk were required according to Eqns. 1-3, where I x is the intensity from emitter x, I(λ) is the intensity measured at wavelength λ, and x σ λ is a correction factor for emission overlap, as defined in the SI (Eqns. S1-S3).
(2)
PL ratios, ρ, were then calculated according to Eqns. 4-5.
In assays, the PL ratios were normalized to the control sample (see Eqn. S4 for details) and then converted into the number of Cy3 and A647 acceptors per QD524, M and N respectively, from empirical calibration functions, ρ Cy3/QD524 (M, N) and ρ A647/QD524 (M, N), Eqn. 6 and Eqn. 7, derived from three-dimensional plots of ρ Cy3 and ρ A647 versus (M, N) (see SI, Fig. S3 ).
ρ A647/QD524 = 4.88
Analytical parameters, k and Δ, were derived from (M, N) versus time data. Aptamer progress curves, M versus time, were fit with a monoexponential function, Eqn. 8, where A is an amplitude, t is time, m reflects the displacement kinetics, and M ∞ is the apparent equilibrium value of M. When mt was sufficiently small (i.e., little or no response), Eqn. 8 reduced to a linear function for data fitting (see SI for justification). Progress curve fits were reduced to a single parameter, Δ, according to Eqn. 9, representing the relative change in the number of cHD1 (Cy3) per QD.
Proteolysis data, N versus time, was fit with a biexponential function, Eqn. 10, where k i is an empirical rate of peptide hydrolysis with amplitude A i , and N ∞ is the residual value of N. These parameters were constrained so that N(0) was equal to the value calculated for the control
sample. An average hydrolysis constant, k, was calculated using Eqn. 11.
several important elements into its physical design. The central QD524 donor was coated with DHLA-PEG ligands to impart robust colloidal stability. The DHLA moiety tightly binds to the ZnS shell of the CdSeS/ZnS core/shell QDs and the PEG moiety resists the non-specific adsorption of many biomolecules and pH-or ionic strength-induced aggregation. 17 Indeed, we found that even low concentrations of human α-thrombin were able to aggregate QDs coated with DHLA or glutathione, whereas DHLA-PEG-coated QDs remained stable. The Sub(A647)
peptide had an N-terminal polyhistidine peptide sequence to permit high-affinity, stoichiometric self-assembly to the ZnS shell of the QDs. 20, 21 The polyhistidine tag is able to penetrate the DHLA-PEG ligand coating and coordinate directly to the inorganic surface of the ZnS shell. 20, 21 Similarly, the HD1p aptamer was appended with a polyhistidine peptide (Cys-His 6 ; see Table 1) using disulfide exchange. 19 Gel electrophoresis confirmed assembly of both peptide and aptamer to QDs (see Fig. S1 ). Sub(A647) contained the LVPRGS amino acid sequence, which is recognized and hydrolyzed by thrombin, 22 resulting in changes in both QD524→A647 and Cy3→A647 FRET (the arrow indicates the direction of energy transfer). Thrombin has a preference for hydrolysis after arginine in the P1 position, with proline at P2 and either serine, threonine, or glycine at P1ʹ. 23 The HD1p aptamer was hybridized with cHD1(Cy3), a partially complementary Cy3-labeled oligonucleotide, to yield changes in QD524→Cy3 and Cy3→A647
FRET upon thrombin-binding. The cHD1(Cy3) sequence was shorter than HD1p, hybridizing to only part of the thrombin-binding HD1 sequence, as reported previously. 16 However, we found that a mismatch had to be incorporated to facilitate displacement of cHD1(Cy3) by thrombin.
Without a mismatch, the kinetics of displacement were very slow (> 4 h) at room temperature.
Assays with active enzymes. The cFRET probe was first tested against thrombin. Given the probe design, thrombin was expected to hydrolyze the Sub(A647) peptide and displace the cHD1(Cy3) oligonucleotide from the QD524 when it was bound by HD1p aptamer. Figure 2A(i) shows changes in the Cy3/QD524 and A647/QD524 PL ratios, as a function of time, when the cFRET probe was exposed to increasing amounts of thrombin (11 nM-5.6 µM). Decreases in these ratios reflected the loss of the QD524→Cy3 and the QD524→A647 plus Cy3→A647
FRET pathways, respectively. Conversion of the PL ratio data to progress curves (i.e., the approximate number of Cy3 and A647 per QD as a function time) gave the expected trends, as shown in Figure 2A (ii). This conversion was done using calibration curves that correlated PL ratios with the numbers of cHD1(Cy3) and Sub(A647) per QD (see Fig. S3 ). With increasing concentrations of thrombin, the rate of hydrolysis of Sub (A647) Next, the cFRET probe was tested against trypsin and lysozyme. Trypsin, like thrombin, is a serine protease that hydrolyzes peptide bonds C-terminal to arginine residues, 24 and was therefore expected to exhibit thrombin-like activity toward Sub(A647) peptide but not bind with
HD1p aptamer. Figure 2B shows progress curves in response to four concentrations of trypsin To reduce the progress curves for hydrolysis of Sub(A647) peptide substrates and displacement of cHD1(Cy3) aptamer complements to single numerical parameters, and to help account for apparent offsets between samples, the progress curve data in Figure 2 were fit to mathematical functions (see Experimental Section, eqns. 8-11). The Sub(A647) data was reduced to an average hydrolysis constant, k (min -1 ), and the displacement of cHD1(Cy3) was reduced to a relative change in the number of cHD1(Cy3) per QD, Δ (unitless). The progress curve data in Figure 2 , summarized in terms of k and Δ, is shown in Figure 3 . The kinetic trends observed in Figure 2 were reflected in the trends in k and Δ. Notably, both k and Δ increased with increasing concentration of active thrombin, only k increased in response to trypsin, and both k and Δ were close to baseline values for lysozyme. The empirical k value was found to be a more robust and more sensitive reduction of the progress curve data than calculation of initial proteolytic rates, and calculating Δ as a relative change was more robust than calculation of an absolute change. Assays with inhibited thrombin. To further evaluate the overall selectivity of the cFRET probe, assays were done with both reversibly and irreversibly inhibited thrombin. To reversibly inhibit thrombin, argatroban was used. Argatroban is a small molecule, direct inhibitor of thrombin with clinical applications and rapid anti-thrombin action via binding with the active site of the protease; the inhibition constant is reported to be 39 nM. 25 We tested the cFRET probe against a two-dimensional series of increasing thrombin and argatroban concentrations. An example of progress curves for this experiment are shown in Figure 4A (i) and the raw PL data can be found in the SI. Increases in the concentration of argatroban had no significant effect on the number of HD1p/cHD1(Cy3) aptamer hybrids per QD524 but markedly decreased the rate of hydrolysis of Sub(A647) peptide. Increases in the concentration of thrombin were able to diminish the level of inhibition from the argatroban. Figure 4A (ii) shows these trends in terms of k and Δ, where k decreased with increasing concentrations of argatroban and increased with increasing concentrations of thrombin, and Δ was insensitive to argatroban but increased with increasing concentrations of thrombin. All of these results were consistent with expectations for reversible inhibition of thrombin at the active site. To irreversibly inhibit thrombin, treatment with an excess of TLCK was utilized. Unlike argatroban, which non-covalently binds to the active site of thrombin, TLCK alkylates the active site at the histidine residue in the histidine-aspartic acid-serine catalytic triad. 26 Figure 4B Effect of co-assembling aptamer and peptide substrate. Given that the HD1 aptamer has been reported to be an inhibitor of thrombin activity, 27 we evaluated the effect that co-localizing Sub(A647) and HD1p on a common QD scaffold had on the proteolytic activity of thrombin toward Sub(A647). avoiding assembly to the QD). As shown in Figure 5 , increasing amounts of aptamer decreased proteolytic activity in both cases; however, the inhibitory effect of HD1p aptamer in bulk solution was greater than with the HD1p aptamer bound to the QD (i.e., cFRET probe). Coconjugation of the Sub(A647) peptide probe and the HD1p aptamer to a common QD scaffold appeared to partially mitigate the inhibitory effects of the latter. 
Discussion
The cFRET probe was multifunctional, utilizing two mechanisms of biorecognition and multiple FRET pathways to signal the concentration and activity of thrombin via changes in the ratiometric PL of the QD524, Cy3, and A647. Quantitative data was obtained by pre-calibration of these PL ratios. The conversion of raw PL data to M and N, the number of each probe per QD, was sensitive to nanomolar concentrations of thrombin and selective for concentration and activity, respectively, as designed. The PL response had some limited sensitivity toward nonspecific secondary effects as trypsin and lysozyme, in sufficient concentration, caused offsets in the progress curves. However, these offsets were static for concentrations of lysozyme and trypsin that were comparable to the concentrations of thrombin (up to ≥2.0 µM). Occasional batch-to-batch variation also caused the calculated initial conjugate valences to vary from the nominal M = 12 and N = 8 (e.g., see Fig. 4B ). The effects of these variations and offsets were minimized by fitting the progress curves to obtain ∆ and k, which were more robust analytical measurements than one-point measurements of M and N. In terms of ∆ and k, the response of the cFRET probe to lysozyme was negligible, and low concentrations of trypsin yielded only small values of ∆, which approached zero with increasing concentration because the aforementioned offsets in PL ratio became effectively instantaneous. The reason for the small ∆ response to trypsin is unclear, but trypsin also evolved a non-specific response from QD524-[HD1p/cHD1(Cy3)] 12 conjugates in the two-probe non-cFRET system (see Fig. S11 ). Nonspecific interactions between trypsin and QDs have been previously reported to cause similar offsets in FRET ratios and calculated conjugate valences in other systems. 28 The response to trypsin is thus not an artifact of the cFRET system, but rather a physical phenomenon. Given that the ∆ offsets were (i) too rapid to be related to displacement of cHD1(Cy3), (ii) decreased with increases in trypsin concentration; and (iii) reached an equilibrium, all of which is inconsistent with non-specific hydrolysis, we speculate that these offsets arise from a non-specific interaction between the QDs and trypsin. In complex biological media, the high-concentration protein background is also expected to cause a static offset that does not interfere with detection via k and ∆. Alternatively, it should be possible to minimize or eliminate these effects, and improve precision, with further optimization of QD materials, surface chemistry, and biorecognition probes.
The reduced inhibitory effects of HD1p aptamer on thrombin when co-conjugated to a QD scaffold with Sub(A647) substrate may be an outcome of one or more of the following factors: a dynamic binding equilibrium between the thrombin and HD1p aptamer, where thrombin dissociates and sees a high local concentration of Sub(A647) at the QD interface; reduced affinity between thrombin and HD1p aptamer when the latter is conjugated to the QD and partially hybridized with cHD1(Cy3) (our data indicates K d ≈ 160 nM, which is higher than the 34 nM reported elsewhere 29 ); and an enhancement of proteolytic activity when substrate is conjugated to a QD. 30 The trend of a decrease in proteolytic activity with increasing numbers of HD1p aptamer per QD may be a result of greater binding between thrombin and HD1p at the expense of interactions between thrombin and Sub(A647), increased steric hindrance that limits the accessibility of Sub(A647) to thrombin, or a combination of these two factors. As the Sub(A647) peptide is much smaller than HD1p aptamer, the Sub(A647) is not expected to sterically hinder interactions between thrombin and HD1p; however, steric interactions between multiple HD1p aptamers on a common QD nanoparticle could potentially contribute to the apparent increase in the K d value noted above. In general, the relative affinities of the aptamer for the protease, as well as the affinity of the protease for the substrate and its turnover, are likely to be important design criteria for cFRET probes of the type described here. The use of aptamers with smaller dissociation constants will likely need to be balanced by the use of peptide probes for which proteases have larger specificity constants.
The ability of the cFRET probe to discriminate between thrombin activity and concentration was predicated on the ability of the HD1p aptamer to bind inhibited thrombin. The HD1 Gquadruplex sequence binds to exosite I of thrombin, 10 such that binding of argatroban and TLCK at the active site of thrombin did not affect the ability of HD1p to bind thrombin. In addition to binding at the active site, regulators of thrombin activity can also bind at exosite I or exosite II. 31 Inhibitors bound at exosite I would interfere with HD1 aptamer-based detection of thrombin concentration, which may be a limitation in some experiments or provide a selectivity advantage in other experiments. Note that these considerations pertain to aptamer selection, and not the cFRET configuration itself. HD22 is another common thrombin-binding aptamer, but this sequence binds to exosite II 10 and therefore would be expected to be sensitive to different thrombin-inhibitor complexes than HD1, providing a further consideration for the design and optimization of future cFRET probes.
The overall multifunctional probe strategy with cFRET is adaptable to other protease targets for which aptamer and substrate sequences are known by substitution of the thrombin-selective sequences. Thrombin was a good initial system for proof-of-concept because its physical and catalytic properties are well-characterized, its aptamer and substrate sequences are well-known, and it has many biological roles in addition to hemostasis (e.g., tumor biology, angiogenesis, inflammation 32 ). Ultimately, cFRET probes of this nature are expected to be highly valuable for analysis and imaging of the dynamics of many proteases in cultured cells or tissues, extracts, and other biological samples. Multifunctional sensing is achieved using a single probe entity and, in principle, retains this functionality from the ensemble down to the level of single particles, minimizing the amount of exogenous probe that must be introduced to a biological system.
Conclusions
We have demonstrated proof-of-concept for a QD-based cFRET configuration that, as a discrete probe, combines two modes of biorecognition to simultaneously and quantitatively detect both protease activity and concentration. Here, thrombin was used as a model system. An aptamer sequence was used to bind thrombin and a peptide substrate was used to measure thrombin activity. FRET signals were generated by partially hybridizing the aptamer with a Cy3-labeled oligonucleotide, and by labeling the distal terminus of the peptide with A647. A central QD524 served as a FRET donor for both of these dyes, with secondary energy transfer between Cy3 and A647. Thrombin displaced these dyes from the QD through different mechanisms, enabling the cFRET probe to distinguish thrombin activity from thrombin-like activity, and distinguish between active, partially inhibited, or completely inhibited thrombin. This format took advantage of both the physical and optical properties of QDs, and is adaptable to other protease targets for which both peptide substrates and binding aptamers are known. 10 This general design for a multifunctional cFRET probe is anticipated to be a valuable tool for real-time measurements of protease activity and regulation. It provides more information than aptamer or peptide probes alone, while also obviating any need for two separate probes. The overall strategy of combining affinity-based and activity-based biomolecule probes on a common nanoparticle scaffold is also likely to benefit the analysis of other classes of enzyme.
